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Although the Ras-related protein TC21/R-Ras2 has only 55% amino acid identity with Ras proteins, mutated
forms of TC21 exhibit the same potent transforming activity as constitutively activated forms of Ras. Therefore,
like Ras, TC21 may activate signaling pathways that control normal cell growth and differentiation. To address
this possibility, we determined if regulators and effectors of Ras are also important for controlling TC21
activity. First, we determined that Ras guanine nucleotide exchange factors (SOS1 and RasGRF/CDC25)
synergistically enhanced wild-type TC21 activity in vivo and that Ras GTPase-activating proteins (GAPs;
p120-GAP and NF1-GAP) stimulated wild-type TC21 GTP hydrolysis in vitro. Thus, extracellular signals that
activate Ras via SOS1 activation may cause coordinate activation of Ras and TC21. Second, we determined if
Raf kinases were effectors for TC21 transformation. Unexpectedly, yeast two-hybrid binding analyses showed
that although both Ras and TC21 could interact with the isolated Ras-binding domain of Raf-1, only Ras
interacted with full-length Raf-1, A-Raf, or B-Raf. Consistent with this observation, we found that Ras- but not
TC21-transformed NIH 3T3 cells possessed constitutively elevated Raf-1 and B-Raf kinase activity. Thus, Raf
kinases are effectors for Ras, but not TC21, signaling and transformation. We conclude that common upstream
signals cause activation of Ras and TC21, but activated TC21 controls cell growth via distinct Raf-independent
downstream signaling pathways.
Ras is a member of a large superfamily of small GTPases
that function as regulated molecular switches (6). Ras GDP/
GTP cycling is controlled by two classes of regulatory proteins
(3). Whereas guanine nucleotide exchange factors (GEFs;
GRF/CDC25 and SOS1/2) function as positive regulators and
promote formation of active Ras-GTP (3, 22, 61), GTPase-
activating proteins (GAPs; p120-GAP and NF1-GAP) are neg-
ative regulators and greatly accelerate the intrinsic GTPase
activity of Ras to promote formation of inactive Ras-GDP (4).
Growth factors, cytokines, hormones, and other extracellular
stimuli cause transient activation of Ras primarily through
upregulation of Ras GEF activity (61). Mutations that activate
Ras transforming potential (at residue 12, 13, or 61) render
Ras insensitive to GAP stimulation, and consequently, these
oncogenic proteins persist in a constitutively activated state (4,
6). Chronic upregulation of Ras, in the absence of mutations in
Ras itself, can also be caused by the loss of GAP function. For
example, the loss of NF1-GAP in some tumor cells leads to
greatly elevated Ras-GTP levels, which are important for the
tumorigenic growth of these cells (1, 19).
A well-defined and highly conserved signaling cascade
whereby Ras functions as a critical intermediate relay switch
between upstream receptor tyrosine kinases and a downstream
cascade of serine/threonine kinases has been established in
mammalian cells as well as in Drosophila melanogaster and
Caenorhabditis elegans (21, 37, 54). For example, epidermal
growth factor stimulation of the epidermal growth factor re-
ceptor promotes receptor autophosphorylation, which in turn
recruits the Grb2-SOS1 complex to the plasma membrane,
where SOS1 causes transient activation of Ras (22, 61, 66).
Activated Ras in turn complexes with and activates the Raf-1
serine/threonine kinase (50). Activated Raf-1 phosphorylates
and activates the mitogen-activated protein kinase (MAPK)
kinase, designated MEK, which in turn activates the p42 and
p44 MAPKs (18, 45). Activated MAPKs translocate from the
cytoplasm to the nucleus, where they activate the Elk-1 tran-
scription factor as well as other proteins (47). The essential
role of Ras and Ras-mediated signaling activity in normal
cellular function has been demonstrated by the use of domi-
nant negative Ras proteins. The H-Ras(17N) and H-Ras(15A)
mutant proteins exhibit impaired GDP/GTP-binding proper-
ties that cause them to form nonproductive complexes with
Ras GEFs, thereby preventing GEF activation of endogenous
Ras (12, 23, 36, 58, 67). The potent growth-inhibitory activities
of Ras dominant negative proteins demonstrate that Ras-me-
diated signaling is essential for normal cellular proliferation.
Although there is substantial evidence that the Raf/MEK/
MAPK pathway is essential for Ras function (16, 39, 43, 46),
there is increasing evidence that Ras mediates its actions
through interaction with multiple downstream effector targets
(73). First, genetic studies of fission yeast Schizosaccharomyces
pombe Ras (ras1) function have identified two distinct ras1
effector-mediated activities (11). One involves ras1 interaction
with byr2 (a MEK kinase homolog), and the other involves
ras1 interaction with scd1 (a putative Rho GEF) (11). scd1, in
turn, may regulate the function of the cdc42sp Rho family
protein. Oncogenic Ras transformation of mammalian cells
has also been shown to be dependent on Rho protein function
(38, 55–57). Second, the existence of Raf-independent Ras
signaling pathways is suggested by the identification of addi-
tional candidate Ras effectors. These include GEFs for the
Ras-related protein Ral (RalGDS and RGL) (33, 40, 69),
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6132
threonine kinase (64), the two Ras GAPs (4), Rin-1 (29), and
AF6 (72). Like Raf-1, these functionally diverse proteins show
preferential binding to the active GTP-bound form of Ras, and
this interaction requires an intact Ras core effector domain
(amino acids 32 to 40) (48). Third, the determination that
effector domain mutants of Ras, which have lost the ability to
bind to and activate Raf-1, still retain potent transforming
activity demonstrates that Ras interaction with other effectors
contributes to Ras transformation (35, 39, 74). Finally, since
Ras, but not Raf, causes transformation of RIE-1 and other
epithelial cells (52), it is clear that Ras activation of the Raf/
MAPK pathway alone is not sufficient for Ras transformation
of some cells. Thus, Ras mediates transformation by activating
both Raf-dependent and Raf-independent pathways.
Although Rap1A and TC21/R-Ras2 have 55% amino acid
identity with Ras and 100% identity with the Ras core effector
domain, only constitutively activated mutants of TC21 cause
cellular transformation (10, 28). Instead, Rap1A antagonizes
Ras signaling and transformation (15, 41, 42). The failure of
Rap1A to cause transformation is surprising in light of the
ability of Rap1A to interact with the Ras-binding domain of
Raf-1 and other candidate Ras effectors (e.g., RalGDS) when
analyzed in yeast two-hybrid or in vitro binding assays (69, 76).
However, Rap1A fails to activate the same downstream sig-
naling pathways as Ras, which suggests that Rap1A does not
functionally interact with and activate the same effector targets
as Ras. In contrast, we have shown that transforming mutants
of TC21 cause constitutive activation of MAPKs and stimulate
transcription from promoters containing Ras-responsive DNA
elements (28). However, it is not known whether TC21 utilizes
Ras effectors, or TC21-specific effectors, to mediate its signal-
ing and transforming actions.
The morphologic and growth-transforming activity caused
by aberrant TC21 function suggests that TC21 is involved in
regulating signaling pathways that control normal cell growth
(10, 28). However, the identities of extracellular stimuli that
activate TC21 and TC21-dependent signaling pathways are not
known. To identify a role for TC21 in normal cell function, we
determined if TC21 function is controlled by the positive and
negative regulators that control Ras GDP/GTP cycling and if
activated TC21 utilizes Raf kinases to promote cellular trans-
formation. First, we found that normal TC21 is sensitive to Ras
GEFs and GAPs, which suggests that extracellular stimuli that
activate Ras via these Ras regulators will also activate TC21.
Second, we found that Ras, but not TC21, could interact with
full length Raf-1, A-Raf, and B-Raf and that only Ras-trans-
formed cells showed constitutive upregulation of Raf kinase
activity. Thus, TC21 transformation is mediated by Raf-inde-
pendent signaling pathways. Finally, TC21 protein expression
showed a more restricted tissue distribution than Ras proteins.
Taken together, these results show that TC21 and Ras have
both common and distinct roles in normal cellular signaling
activities.
MATERIALS AND METHODS
Generation of TC21 mutants and molecular constructs. Oligonucleotide-di-
rected mutagenesis using the Chameleon mutagenesis protocol (Stratagene) was
used to generate mutant tc21 cDNA sequences encoding single amino acid
substitutions at residues that correspond to analogous mutations in H-Ras(15A)
and H-Ras(17N) dominant negative mutants, designated TC21(26A) and
TC21(28N), respectively. All mutant cDNA sequences were generated in a
0.7-kb BamHI fragment that contains the full-length human wild-type tc21
cDNA sequence. TC21(26A) contains a Gly (GGC)-to-Ala (GCC) mutation that
corresponds to Ras residue 15, whereas TC21(28N) contains a Ser (TCG)-to-Asn
(AAT) mutation that corresponds to Ras residue 17. In the process of site-
directed mutagenesis, the first KpnI site in the 39 noncoding region was converted
to a BamHI site. Each mutant tc21 sequence was introduced into the unique
BamHI restriction site of a modified pZIP-NeoSV(x)1 retrovirus vector (9). All
mutated sequences were verified by dideoxy sequencing with a Sequenase kit
(U.S. Biochemical/Amersham) according to the manufacturer’s instructions.
Cell culture and transformation/inhibition assays. NIH 3T3 cells were cul-
tured in Dulbecco’s modified Eagle’s medium supplemented with 10% calf
serum. DNA transfections were performed as described previously, using the
calcium phosphate precipitation technique (13). Cells were transfected with, per
dish, 0.1 to 1 mg (for Ras GEF assays) or 50 to 100 ng (dominant negative
inhibition assays) of pZIP plasmid DNA encoding wild-type TC21 [TC21(WT)]
or mutant TC21 protein. Focus inhibition assays were done by transfection of
either pZIP-rasH(61L) or pZIP-tc21(72L) (10 ng) alone or together with pZIP-
Krev-1(63E) plasmid DNA. Krev-1(63E) is a constitutively activated mutant
which exhibited stronger inhibition of Ras transformation than its wild-type
counterpart (41). The appearance of transformed foci was quantitated after 14
days. Growth inhibition was assessed by selecting transfected cells in growth
medium supplemented with G418 (GIBCO/BRL) at 400 mg/ml. After approxi-
mately 14 days, cells were fixed and stained with 0.4% crystal violet.
In vitro GTP hydrolysis and GDP/GTP exchange assays. cDNA sequences
encoding TC21(WT) or TC21(72L) were introduced into the pGEX-2T bacterial
expression vector to generate glutathione S-transferase (GST)–TC21 chimeric
proteins (8), which were purified as described previously (68) and quantitated by
using Bradford reagents. Purified, bacterially expressed H-Ras (residues 1 to 166;
obtained from S. Campbell, University of North Carolina at Chapel Hill) and
GST-TC21 proteins were preloaded with [g-32P]GTP and incubated (400 or 420
ng, respectively), either alone or with purified full-length p120-GAP or the
catalytic domain of NF1-GAP (designated NF1-GRD) (at a 1:4 molar ratio with
H-Ras or TC21 obtained from S. Campbell). GTP hydrolysis within 30 min at
room temperature was measured by the cleavage of the radiolabeled phosphate
in an organic phosphate release assay as described previously (5).
Transcription activation assays. To determine the ability of Ras exchange
factors to activate TC21(WT) transforming activity, NIH 3T3 cells were tran-
siently cotransfected with 750 ng of pZIP-tc21(WT), either alone or together
with either pZIP-cCDC25/CAAX or pZIP-cSOS/CAAX (150 ng or 1 mg, respec-
tively). Activation of Elk-1 was determined by cotransfection with Gal4–Elk-1,
which encodes a fusion protein containing the Gal4 DNA-binding domain to-
gether with the transactivation domain of Elk-1 (containing MAPK phosphory-
lation sites) and Gal4-Luc, which contains the luciferase gene driven by a min-
imal promoter containing tandem Gal4 DNA-binding sites (provided by R.
Treisman) (47). Approximately 48 h after transfection, cell lysates were pre-
pared, and the luciferase activity induced by each pZIP-tc21 or pZIP-rasH
construct was assayed in a luminometer, using procedures which we have de-
scribed previously (32). To determine the ability of the Raf-N4 dominant nega-
tive mutant (17) to block TC21 signaling activity, NIH 3T3 cells were transiently
cotransfected with 100 ng of pZIP-tc21(72L) plasmid DNA, either alone or
together with 3 mg of pCGN-raf-N4 or pCGN-raf(WT) and 150 ng of Gal4–Elk-1
and 2.5 mg of Gal4-Luc. Raf-N4 is a COOH-terminally truncated, kinase-defi-
cient mutant which retains the two NH2-terminal Ras-binding domains of Raf-1
and functions as a dominant negative mutant by blocking Ras interaction with
Raf-1 and other candidate effector proteins (17).
Raf kinase assays. Raf kinase activities were measured by using an in vitro
coupled kinase assay in which the ability of immunoprecipitated Raf to activate
MEK phosphorylation of MAPK was determined. Briefly, NIH 3T3 cells stably
transfected with the empty pZIP-NeoSV(x)1 vector, or expressing TC21(72L) or
H-Ras(61L) protein, were subjected to immunoprecipitation with Raf-specific
antisera generated against c-Raf-1 and B-Raf [Raf-1(C-12) and Raf-B(C-19),
respectively; Santa Cruz Biotechnology]. The immune complexes were collected
on protein A-conjugated Sepharose beads. Beads with their attached immune
complexes were incubated with [g-32P]ATP and purified recombinant wild-type
MEK protein, a known substrate of Raf kinase (provided by Qiming Chen,
University of North Carolina at Chapel Hill). After 15 min, these complexes were
then incubated with recombinant kinase-deficient MAPK, a known substrate of
MEK (provided by Qiming Chen), and the reaction mixture was incubated for a
further 15 min. The reaction was stopped by the addition of 23 protein sample
buffer, and the proteins were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and stained with Coomassie blue to ensure that
equal loading had taken place. The dried gel was then exposed to a Bio-Rad
PhosphorImager to quantitate the amount of 32P transferred onto MAPK.
Yeast two-hybrid analysis. Yeast two-hybrid binding analyses were done es-
sentially as described previously (73). Briefly, we used a modification of the
Fields two-hybrid system (24) wherein one hybrid is a fusion between the LexA
DNA-binding domain (amino acids 1 to 211) and either H-Ras(12V) or
TC21(WT) sequences. The second hybrid is a fusion between a nucleus-localized
VP16 acidic activation domain and the full-length sequences of human c-Raf-1,
A-Raf, and B-Raf or the NH2-terminal Raf-1 sequences which contain a minimal
Ras-binding domain. Individually, these hybrids are unable to activate transcrip-
tion. However, when coexpressed in a Saccharomyces cerevisiae strain that con-
tains two integrated reporter constructs (yeast HIS3 and the bacterial lacZ gene)
which contain binding sites for the LexA protein, successful interactions bring
the DNA-binding domain of LexA into the proximity of the transactivation
domain of VP16 and allow transcription. The yeast strain expressing both hybrid
proteins that are capable of forming interactions are prototropic for histidine and
contain detectable b-galactosidase activity. Interaction between the H-Ras or
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TC21 fusions and Raf fusions were performed in the S. cerevisiae reporter strain
YPB2 and assayed for b-galactosidase activity on filters.
Tissue expression of TC21 protein. Lysates of human adult tissues (Clontech)
were resolved by SDS-PAGE (60 mg of total protein per lane) and Western
blotted (immunoblotted) with an affinity-purified anti-TC21 rabbit polyclonal
antibody, which was made against bacterially expressed recombinant TC21 pro-
tein (14). This antiserum does not recognize Ras proteins but shows very weak
recognition of the related R-Ras protein.
RESULTS
TC21(WT), but not transforming TC21, is negatively regu-
lated by p120-GAP and NF1-GAP. Ras GAPs require an intact
Ras core effector domain (Ras residues 32 to 40) to bind to and
stimulate the intrinsic GTPase activity of wild-type Ras pro-
teins (48, 53). However, although Rap1A has complete amino
acid identity with the Ras core effector domain, it is insensitive
to Ras GAPs (25, 31). Thus, although TC21 also has complete
identity with the Ras core effector domain, it was not obvious
whether TC21 is sensitive to Ras GAPs. To determine if
TC21(WT) is sensitive to this stimulation, we expressed recom-
binant GST fusion proteins containing TC21(WT) and
TC21(72L) sequences and performed in vitro GTP hydrolysis
assays. Bacterially expressed wild-type H-Ras [H-Ras(WT)]
protein was used as a control for these studies.
Purified TC21 and H-Ras proteins were first preloaded with
radiolabeled [g-32P]GTP and then incubated either with or
without purified recombinant versions of p120-GAP or the
NF1-GAP catalytic domain (NF1-GRD). Comparable to ob-
servations with H-Ras(WT), TC21(WT) displayed very weak
intrinsic GTPase activity that could be greatly accelerated (sev-
enfold) by the addition of p120-GAP (Fig. 1). However, unlike
H-Ras(WT), TC21(WT) GTPase activity was only weakly stim-
ulated by the addition of NF1-GRD (2.5-fold stimulation).
Thus, both Ras GAPs can stimulate GTP hydrolysis on
TC21(WT) in vitro, although p120-GAP is more efficient. Fi-
nally, like oncogenic mutants of Ras (3), the transforming
TC21(72L) mutant showed a very reduced intrinsic GTPase
activity which was not further stimulated by either Ras GAP
(Fig. 1). Therefore, Ras GAPs can act as negative regulators of
TC21, and loss of GAP responsiveness may be responsible for
activating the transforming potential of TC21(72L).
TC21 is positively regulated by Ras GEFs SOS1 and Ras-
GRF/CDC25. We and others have shown that H-Ras residues
in the region spanning amino acids 63 to 76 are important for
H-Ras GEF binding and stimulation of GDP/GTP exchange
(51, 58, 60). Among Ras-related proteins, TC21 and the closely
related R-Ras protein (70% overall identity with TC21) show
the strongest sequence identity with Ras in this region (27).
However, since R-Ras is insensitive to Ras GEF stimulation
(34), we anticipated that TC21 would not be activated by Ras
GEFs. To address this possibility, we first examined whether
purified Ras GEFs could stimulate TC21(WT) activity in vitro,
by performing guanine nucleotide exchange assays on purified
recombinant TC21(WT) protein. However, we found that in
contrast to H-Ras(WT), TC21(WT) showed a very high intrin-
sic exchange activity in vitro (data not shown). Thus, we were
unable to accurately measure any potential further stimulation
of this activity by the addition of Ras GEFs. Therefore, we
then used several in vivo assays that indirectly measure the
abilities of Ras GEFs to activate Ras function to determine if
SOS1 or RasGRF/CDC25 can also activate TC21(WT).
First, we examined whether overexpression of Ras GEFs
would synergistically enhance TC21(WT) downstream signal-
ing. For these assays, we determined the consequences of Ras
GEF overexpression on the ability of TC21(WT) to activate
Elk-1 transcriptional activity by using a transient-transfection
luciferase assay. For this analysis, we used a plasmid expression
vector encoding the catalytic domain of human RasGRF/
CDC25 (cCDC25/CAAX) or mouse SOS1 (cSOS or cSOS/
CAAX) (59). Transfection of pZIP-tc21(WT), pZIP-rasH(WT),
pZIP-cSOS1, or pZIP-cCDC25/CAAX alone caused only lim-
ited stimulation of luciferase activity (2.2- to 5.5-fold) (Fig.
2A). As shown previously, coexpression of cCDC25/CAAX or
cSOS1/CAAX synergistically enhanced H-Ras(WT) activity
(2.1- and 2.9-fold, respectively, above the additive level). Sim-
ilarly, coexpression of cSOS/CAAX with TC21(WT) caused a
synergistic enhancement of Elk-1 activity (2.7-fold above the
additive level). However, coexpression of cCDC25/CAAX did
not cause significant enhancement of TC21(WT) activity.
Next, we determined if overexpression of Ras GEFs could
synergistically enhance TC21(WT) transforming activity in
NIH 3T3 focus formation assays. Transfection of 1 mg of pZIP-
rasH(WT) or pZIP-tc21(WT) plasmid DNA alone caused very
low focus-forming activity. However, cotransfection with the
Ras GEF-expressing plasmids caused synergistic enhancement
of H-Ras(WT) and TC21(WT) focus-forming activity (Fig.
2B). Whereas coexpression of either Ras GEF caused approx-
imately 2-fold synergistic enhancement of H-Ras(WT) focus-
forming activity, cSOS caused a greater enhancement than
cCDC25/CAAX of TC21(WT) focus-forming activity (8.9- and
2.6-fold, respectively, above the additive level).
We also used an indirect assay to determine whether Ras
GEFs can interact with TC21(WT). The H-Ras(15A) and
H-Ras(17N) dominant negative proteins cause potent inhibi-
tion of cell proliferation as a result of their ability to antagonize
Ras GEF activation of Ras (12, 36, 67). Therefore, we deter-
mined if analogous mutants of TC21(WT), designated
TC21(26A) and TC21(28N), would also cause inhibition of cell
growth. To examine this, we introduced both TC21(26A) and
TC21(28N) into a mammalian expression vector that also con-
tains the drug-selectable marker for G418 [Neor; pZIP-
NeoSV(x)1]. NIH 3T3 cells transfected with these plasmids
were grown in growth medium supplemented with G418 to
select for drug-resistant colonies stably expressing TC21(26A)
or TC21(28N) protein. Like the H-Ras dominant negative
proteins, we found that cultures transfected with the expres-
sion plasmids encoding these two TC21 mutant proteins re-
sulted in a significant reduction (greater than threefold) in the
appearance of G418-resistant colonies (Fig. 3). Thus, like
FIG. 1. Ras GAPs stimulated the intrinsic GTPase activity of TC21(WT), but
not transforming TC21, in vitro. Purified H-Ras or GST-TC21 proteins were
preloaded with [g-32P]GTP and incubated either alone or with recombinant
p120-GAP and NF1-GRD, and GTP hydrolysis was determined after 30 min at
room temperature. Data shown are the averages of duplicate samples and are
representative of three independent assays.
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H-Ras(15A) and H-Ras(17N), these mutants of TC21 may
function as dominant negative proteins.
We next determined if coexpression of TC21(26A) and
TC21(28N) could block Ras GEF stimulation of H-Ras(WT)
or TC21(WT) transcription activation. For these assays, we
cotransfected a plasmid encoding a chimeric Gal4–Elk-1 pro-
tein together with a reporter plasmid in which luciferase gene
expression is controlled by a minimal promoter containing
tandem Gal4 DNA-binding sequences (47). As we have shown
previously, coexpression of the H-Ras(17N) mutant completely
blocked cSOS1/CAAX stimulation of H-Ras(WT) activation
of Elk-1 (Fig. 4A) (60). Similarly, we found that cotransfection
of an expression plasmid encoding either TC21(26A) or
TC21(28N) also caused a significant inhibition of cSOS1/
CAAX enhancement of H-Ras(WT) transcription activation.
A fivefold increase in the amount of cotransfected pZIP-
cSOS1/CAAX was able to overcome this inhibition (data not
shown). Coexpression of either TC21 mutant protein also in-
hibited cSOS1/CAAX stimulation of TC21(WT) activation of
Elk-1 (Fig. 4B). Although these assays are indirect, when taken
together with the ability of SOS1 to synergistically enhance
TC21(WT) transactivation and transforming activities (Fig. 2),
they provide strong evidence that Ras GEFs are activators of
TC21.
TC21 fails to interact with and cause constitutive activation
of Raf kinases in vivo.We previously showed that transforming
mutants of TC21 caused constitutive activation of p42 and p44
MAPKs and activated transcription from both ets/AP-1 and
NF-kB Ras-responsive promoter elements (28). Since TC21
has complete identity with the Ras core effector domain (27),
we suspected that Raf-1 functioned as the critical effector for
causing these activities. However, since Raf-independent
mechanisms of MAPK activation have been described (75), it
is also possible that TC21 activates these downstream events
via other effectors. To address this possibility directly, we de-
termined whether a Raf-1 dominant negative mutant could
block TC21 transforming activity, whether TC21 could associ-
ate with the three Raf kinases in yeast two-hybrid binding
assays, and whether Raf kinases are constitutively upregulated
in TC21-transformed cells.
Consistent with the critical role of Raf-1 as an effector for
Ras function, dominant negative mutants of Raf-1 have been
shown to potently block oncogenic Ras signal transduction and
transformation (7, 43). Therefore, we determined if a domi-
nant negative mutant of Raf-1, which blocks oncogenic Ras
transformation and signal transduction by forming nonproduc-
tive complexes with Ras, could also block TC21 function. For
these analyses, we used the COOH-terminally truncated
Raf-N4 mutant protein (Raf-1 residues 1 to 256), which con-
tains the two NH2-terminal Ras-binding sequences but lacks
the COOH-terminal kinase domain (7). We previously showed
that coexpression of Raf-N4 inhibited oncogenic Ras signaling
and transformation (7). Whereas coexpression of wild-type
Raf-1 (which alone is not transforming or transcriptionally
active) synergistically enhanced TC21(WT) activity, coexpres-
sion of Raf-N4 blocked TC21(72L)-mediated stimulation of
Elk-1 transcriptional activation (Fig. 5). We also observed that
coexpression of Raf-N4 also greatly inhibited TC21(72L)-in-
duced focus formation (data not shown). These results indi-
cated that this truncated Raf-1 fragment can interact with the
TC21 effector domain in vivo and block TC21 function.
Since Ras interaction with Raf proteins has also been dem-
onstrated in the yeast two-hybrid assay (71, 73, 76), we used
this assay to determine if TC21(WT) could interact with the
FIG. 2. Ras GEFs synergistically enhanced TC21(WT) transactivation and
transforming activity in NIH 3T3 cells. (A) Coexpression of cCDC25/CAAX or
cSOS1/CAAX synergistically enhanced H-Ras(WT) and TC21(WT) stimulation
of Gal4–Elk-1 transcription activation of luciferase from the Gal4-Luc reporter
plasmid in transient-transfection assays using NIH 3T3 cells. Data shown are the
averages of duplicate samples and are representative of three independent as-
says. (B) Coexpression of cCDC25/CAAX or cSOS synergistically increased
H-Ras(WT) and TC21(WT) focus formation in NIH 3T3 cells. The appearance
of transformed foci was quantitated after 14 to 16 days. Data shown are the
averages of four dishes and are representative of three independent assays.
FIG. 3. TC21 mutants analogous to the H-Ras(15A) and H-Ras(17N) dom-
inant negative mutant proteins inhibited the growth of NIH 3T3 cells. NIH 3T3
cells were transfected with 50 or 100 ng of pZIP-NeoSV(x)1 retrovirus expres-
sion vector plasmid DNA constructs (Neor) encoding wild-type or mutant forms
of H-Ras or TC21. The appearance of G418-resistant colonies was visualized by
staining with crystal violet after 14 to 16 days. A reduction in the appearance of
G418-resistant colonies was used as a measure of growth inhibition. Cultures
transfected with expression vectors of TC21(26A) and TC21(28N) caused a
reduction in the appearance of G418-resistant colonies compared with cultures
transfected with either empty vector (data not shown) or a vector encoding
TC21(WT). Data are representative of three separate experiments.
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three Raf family proteins. Expression plasmids encoding the
LexA DNA-binding domain (amino acids 1 to 211) fused to
TC21 or H-Ras were coexpressed in S. cerevisiae with expres-
sion plasmids encoding the VP16 acidic activation domain
fused to the full-length sequences of Raf-1, B-Raf, and A-Raf
or to a truncated Raf-1 fragment which contains only a mini-
mal Ras-binding domain (Raf-1 residues 51 to 130; designated
Raf-RBD). Surprisingly, whereas both TC21 and H-Ras
showed interaction with Raf-RBD, only H-Ras interacted with
the full-length versions of the three Raf proteins (Fig. 6).
While these results were consistent with the ability of a trun-
cated Raf-1 dominant negative mutant protein to block TC21
function in NIH 3T3 cells, they suggested that H-Ras, but not
TC21, interacted with authentic full-length Raf proteins in
vivo.
In light of the yeast two-hybrid results, we addressed the
possibility that Ras, but not TC21, transformation caused con-
stitutive Raf kinase activation in NIH 3T3 cells. For these
analyses, we immunoprecipitated c-Raf-1 or B-Raf from either
untransformed control (vector-transfected) NIH 3T3 cells or
H-Ras- or TC21-transformed cells (62). The immunoprecipi-
tated Raf protein was then incubated with recombinant MEK
and kinase-deficient MAPK to measure Raf activation of MEK
to phosphorylate MAPK in an in vitro coupled assay. Whereas
H-Ras(61L)-transformed cells showed constitutively elevated
c-Raf-1 and B-Raf kinase activities, TC21(72L)-transformed
cells showed the same low kinase activity as seen in untrans-
formed NIH 3T3 cells (Fig. 7). These results, taken together
with those of our yeast two-hybrid binding analysis, show that
TC21 neither interacts with nor activate Raf kinases in vivo.
Krev-1/Rap1A antagonizes TC21 focus-forming activity.
The Ras-related protein Krev-1/Rap1A has been shown to
antagonize Ras signaling and transformation, presumably be-
cause Krev-1 forms inactive complexes with critical Ras effec-
FIG. 4. Dominant negative mutants of TC21 inhibited SOS1 synergistic stimulation of H-Ras(WT) or TC21(WT) transcription activation. Transient transfection
assays were done with NIH 3T3 cells to measure the ability of pZIP-cSOS1 (1 mg) to stimulate H-Ras(WT) (500 ng) (A) or TC21(WT) (750 ng) (B) transcription
activation of a Gal4–Elk-1 chimeric protein to stimulate luciferase expression from the Gal4-Luc reporter plasmid. Coexpression of TC21(26A) or TC21(28N) (3 mg)
was done to determine if these dominant negative mutant proteins could inhibit cSOS1 stimulation. H-Ras(17N) (3 mg) was used as a control for these assays. RLU,
relative luciferase units. Data are averages of duplicate samples and are representative of three independent assays.
FIG. 5. Coexpression of the Raf-N4 dominant negative mutant inhibited
H-Ras(61L) and TC21(72L) transcription activation of Elk-1. Transient trans-
fection assays were done in NIH 3T3 cells to measure the ability of the Raf-N4
dominant negative protein, which contains only the Ras-binding domains of
human Raf-1, to block the ability of transforming mutants of H-Ras and TC21 to
stimulate Gal4–Elk-1 transcription activation of luciferase from the Gal4-Luc
reporter plasmid. Data shown are the averages of two samples, are relative to the
activity seen with cells transfected with the empty vector, and are representative
of three independent assays.
FIG. 6. TC21(WT) interacted with truncated but not full-length Raf pro-
teins. Yeast two-hybrid analysis was done to compare the ability of H-Ras and
TC21 to bind full-length Raf-1, B-Raf, and A-Raf or the isolated Ras-binding
domain of Raf-1. b-Galactosidase activity was determined by filter assay. Yeast
patches containing interacting protein pairs are dark as a result of b-galactosi-
dase activity producing a 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-
Gal) cleavage product. Yeast patches containing noninteracting protein pairs
remain white as a result of the absence of detectable b-galactosidase activity.
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tor targets such as Raf-1. However, since our data suggest that
TC21 causes transformation via a Raf-independent mecha-
nism, we determined if Krev-1 was capable of blocking TC21
transforming activity. To evaluate this, we transfected
TC21(72L) or H-Ras(61L), either alone or together with the
Krev-1(63E) mutant (41), into NIH 3T3 cells and assayed for
inhibition of focus-forming activity. Consistent with previous
studies (41), we found that this Krev-1 mutant caused a greater
than 50% reduction in H-Ras(61L) focus-forming activity (Fig.
8). Unexpectedly, Krev-1(63E) also caused a significant
(.50%) reduction in TC21(72L) focus-forming activity. Since
Raf kinases are not critical effectors for TC21 transformation,
these results suggest that Krev-1 antagonizes Ras and TC21 by
competing with effectors in addition to, or other than, Raf.
TC21 protein is differentially expressed in human tissues.
The three Ras proteins are expressed ubiquitously in all tis-
sues, although higher expression is seen in some tissues (26).
For example, H-Ras expression is highest in the brain (26).
Since our data suggest that Ras and TC21 proteins have over-
lapping functions, we wanted to determine if TC21 is also
ubiquitously expressed. For these analyses, we used an affinity-
purified anti-TC21 antiserum for Western blot analyses of cell
lysates derived from a spectrum of human tissues. NIH 3T3
cells stably expressing high levels of TC21(WT) from an exog-
enously introduced expression vector were used as a control
for the electrophoretic mobility of human TC21(WT). We
observed that the level of TC21 protein expression varied
widely in the different tissues (Fig. 9). Whereas high TC21
protein expression was seen in kidney, placenta, and ovaries,
no significant expression was seen in brain, testes, or lung
tissue. Low levels were seen in cardiac and skeletal muscle as
well as in liver tissue. The identity of the additional bands that
were detected by this antiserum in some samples (e.g., skeletal
muscle) is not known. These results suggest that in contrast to
Ras proteins, TC21 protein function may be restricted to cer-
tain tissues.
DISCUSSION
We and others have observed that mutant forms of TC21
show transforming potencies which are comparable to those
seen with oncogenic forms of the three Ras proteins (10, 28).
Thus, like Ras, TC21 is likely to regulate signaling pathways
that influence cell growth and differentiation. However, the
extracellular signal-mediated signaling pathways that cause
TC21 activation, and the effectors which are stimulated by
activated TC21, have not been identified. To begin to define
these pathways, we determined if TC21 function is controlled
by Ras regulators and effectors. First, we found that Ras GEFs
and GAPs can function as positive and negative regulators of
TC21. These results suggest that extracellular signals that ac-
tivate Ras via upregulation of Ras GEF, or downregulation of
Ras GAP, function are likely to cause a coordinate activation
of TC21. Second, we observed that H-Ras, but not TC21,
interacted with and activated Raf-1 and B-Raf kinases. There-
fore, whereas Raf kinases are clearly important effectors for
Ras transformation, TC21 causes transformation via Raf-inde-
pendent signaling events. Finally, we found high TC21 protein
expression in kidney, placenta, and ovaries, but no detectable
expression was seen in brain, testes, or lung tissue. This ex-
pression pattern is distinct from those described for the three
Ras proteins and suggests that TC21 function is more re-
stricted than that of Ras proteins. Taken together, these ob-
servations show that TC21 possesses functions which are both
common to and distinct from those of Ras proteins.
While we were not able to determine directly that Ras GEFs
could stimulate GDP/GTP exchange in vitro, we used two in
vivo assays to demonstrate that Ras GEFs could regulate TC21
function. First, we showed that SOS1 overexpression synergis-
tically enhanced TC21(WT) stimulation of Elk-1 transcrip-
tional activity and focus-forming activity. Second, we showed
FIG. 7. Oncogenic H-Ras(61L)- but not TC21(72L)-transformed NIH 3T3
cells showed elevated Raf-1 and B-Raf kinase activities. Raf-1 or B-Raf was
immunoprecipitated from cell lysates of equivalent cell numbers of NIH 3T3
cells stably expressing H-Ras(61L) or TC21(72L). In vitro Raf kinase assays were
done on immunoprecipitated Raf-1 or B-Raf, using a Raf-immunocomplex cou-
pled kinase assay as described in Materials and Methods. Data are representative
of three independent assays.
FIG. 8. Coexpression of Krev-1/Rap1a inhibited TC21(72L) focus-forming
activity. Cotransfection focus formation assays were done to determine if acti-
vated Krev-1(63E) could block TC21(72L) focus-forming activity in NIH 3T3
cells. Ten nanograms of pZIP-NeoSV(x)1 retrovirus expression plasmid DNA
construct encoding TC21(72L) or H-Ras(61L) was transfected per 60-mm-diam-
eter dish, together with either 2 mg of pZIP-Krev-1(63E) or pZIP-NeoSV(x)1
(empty vector) plasmid DNA. The appearance of transformed foci was quanti-
tated after 14 to 16 days. Data are the averages of four plates and are represen-
tative of two independent assays.
FIG. 9. TC21 protein is preferentially expressed in adult human kidney,
ovary, and placental tissues. Detergent lysates of tissue from the indicated human
organs (provided by Gil White, University of North Carolina at Chapel Hill)
were resolved by SDS-PAGE (equivalent total protein amounts were loaded in
all lanes), transferred to membranes, and Western blotted with affinity-purified
anti-TC21 antiserum. A lysate of NIH 3T3 cells stably transfected with pZIP-
tc21(WT) was used as a positive control for the mobility of TC21(WT) (indicated
by arrow). Antibody binding was detected by enhanced chemiluminescence (Am-
ersham).
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that dominant negative mutants of TC21, like H-Ras mutants
which block Ras GEF function, also blocked SOS1 activation
of H-Ras(WT) and TC21(WT). While these assays are indi-
rect, and do not exclude the possibility that Ras GEF activa-
tion of Ras then enhances TC21 function, our observations
clearly show that Ras GEFs can enhance TC21 function. The
ability of SOS1 to stimulate TC21 was unexpected in light of
our recent observation that the closely related R-Ras protein
(70% identity) was not responsive to either SOS1 or RasGRF/
CDC25 (34). However, these results suggest that extracellular
stimuli that transiently activate Ras, either via upregulation of
GEFs or downregulation of GAPs, will also activate TC21.
Final confirmation of this possibility will require a demonstra-
tion that TC21-GTP levels are upregulated by the same stimuli
that activate Ras. Since our preliminary analyses have found
that the currently available TC21 antisera are not useful for
assaying GDP/GTP loading in vivo, we have been unable to
directly address this possibility.
The ability of Ras GEFs to activate TC21 also suggests that
the H-Ras(15A) and H-Ras(17N) dominant negative proteins,
which inhibit Ras function by forming inactive complexes with
Ras GEFs (36, 58, 67), are also inhibitors of TC21 function.
Since these dominant negative proteins have been used widely
as reagents to establish the role of Ras in specific signaling
activities (61), it is important to consider the possibility that
TC21 function is also involved in biochemical or biological
activities that are antagonized by dominant negative H-Ras.
Whether TC21 is also activated by additional TC21-specific
GEFs will be important to determine since it is possible that
extracellular stimuli that activate such GEFs will specifically
activate TC21 and not Ras.
We also observed that Ras GAPs can stimulate the low
intrinsic GTPase activity of TC21(WT) and that the biochem-
ical defect in the TC21(72L) transforming mutant is a loss of
GAP sensitivity. Since TC21 is sensitive to NF1-GAP, it is
possible that TC21 activity, like that of Ras, is upregulated in
malignant schwannomas that have lost NF1-GAP activity (1,
19). Hence, the deregulated function of not only Ras but also
TC21 may contribute to the tumorigenic growth properties of
these cells. Alternatively, since the NF1-GRD activity was
weak, it is possible that NF1 is not a physiologically relevant
negative regulator of TC21 function. Finally, it remains possi-
ble that TC21 is also regulated by TC21-specific GAPs which
are not active on Ras proteins.
Although TC21 has complete identity with the Ras core
effector domain, which is required for Ras interaction with
Raf-1, our results showed that TC21 neither binds to nor pro-
motes the activation of Raf kinases. First, we observed that
TC21 failed to bind to full-length Raf kinases in yeast two-
hybrid binding assays. Second, we found that Raf-1 and B-Raf
kinase activities were constitutively elevated in H-Ras- but not
TC21-transformed cells. The ability of TC21 to bind to an
isolated Ras-binding sequence of Raf-1 but not to full-length
versions of the three Raf kinases is not surprising in light of our
recent observations that H-Ras complexes with Raf-1 via two
distinct binding sequences on each protein (7). The conversion
from inactive Ras-GDP to active Ras-GTP causes limited con-
formation changes which are restricted to two regions of Ras,
designated switch I (residues 30 to 38 in the Ras core effector
domain) and switch II (residues 59 to 76) (44, 49). Whereas
Ras switch I residues interact with a Ras-binding domain
within Raf-1 residues 51 to 130, Ras switch II residues are
required for interaction with residues in the Raf-1 cysteine-rich
domain (20). Since mutations in either switch I or II abolish
Ras transforming activity, Ras interactions with both Raf se-
quences are probably required for Ras-mediated activation of
Raf-1 and for Ras transformation (20). Thus, we suspect that
TC21 fails to interact with both Raf-1 domains and conse-
quently fails either to promote Raf translocation to the plasma
membrane or to allow the as yet unidentified events required
to activate Raf kinase at the plasma membrane. Finally, the
ability of an isolated Ras-binding sequence of Raf-1, but not
full length Raf-1, to interact with TC21 shows that binding
analyses done with isolated Ras-binding sequences may not
accurately predict whether interactions will occur with the full-
length counterparts.
We had determined previously that transforming mutants of
TC21 caused constitutive upregulation of p42 and p44 MAPKs
and activated the Elk-1 transcription factor (28). Therefore, we
had anticipated that TC21 would activate these downstream
events by activation of Raf kinases. However, our observations
suggest that TC21 must activate MAPKs via a non-Raf effec-
tor. Since there is evidence for Raf-independent signaling
pathways that cause activation of MAPKs (75), it is likely that
TC21 utilizes other MEK activators, such as MEK kinases, to
activate this pathway.
The ability of TC21 to cause transformation via Raf-inde-
pendent effectors is not surprising in light of recent observa-
tions that Raf-independent pathways are also important for
Ras transforming activity (35, 39, 74). In particular, we found
that two H-Ras effector domain mutants [designated
H-Ras(12V, 37G) and H-Ras(12V, 40C)], which failed to bind
to or activate Raf-1, still retained the ability to cause full
tumorigenic transformation of NIH 3T3 cells. While the effec-
tors used by these two mutants to cause transformation are not
known, they may also represent the key effectors that mediate
TC21 transformation. Thus, it is likely that at least some of the
recently identified candidate Ras effectors, such as phosphati-
dylinositol-3-OH kinase or RalGDS proteins, will be important
effectors of TC21 and Ras transformation.
How Rap1A/Krev-1 antagonizes Ras signaling and transfor-
mation is presently still unresolved. In vitro and yeast two-
hybrid binding analyses have shown that Rap1A can bind to
the Ras-binding domain of Raf and other candidate Ras ef-
fectors. Since Rap1A has been found to exhibit a subcellular
localization to the endoplasmic reticulum and Golgi complex
(2, 65), rather than to the inner surface of the plasma mem-
brane where Ras is found, it has been speculated that Rap1A
may compete for key Ras effectors which are essential for Ras
transforming activity. In the present study, we found that TC21
transforming activity was not mediated through interaction
with Raf kinases, yet TC21 transforming activity is blocked by
Rap1A. Thus, our results suggest that Krev-1 antagonizes both
TC21 and Ras transforming activity by sequestering non-Raf
proteins and provide further support for the importance of
other candidate Ras effectors in Ras transformation.
It is still unclear whether the three Ras proteins (H-, K-, and
N-Ras) exhibit functionally distinct roles in cell physiology.
Since gene knockout studies showed that H-ras- or N-ras-
deficient mice exhibited essentially normal growth and devel-
opment (70), it seems likely that Ras proteins are functionally
redundant. In this study, we show that TC21 is distinct from
Ras and causes transformation by Raf-independent down-
stream signaling. Since a TC21 homolog is also found in D.
melanogaster (30), we suggest that TC21 is likely to have func-
tions which are distinct from those of the three Ras proteins.
Confirmation of this possibility will require the generation of
TC21-deficient mice. Finally, whereas Ras proteins are ex-
pressed ubiquitously, TC21 expression is more restricted. In-
terestingly, TC21 is expressed in tissues (ovaries, kidney, and
liver) which give rise to tumors which typically lack mutated ras
genes. Therefore, it is possible that mutation (10) or overex-
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pression of TC21 is important in the development of neo-
plasms that arise from these tissues. Support for this possibility
is provided by the detection of a mutated and transforming
form of TC21 in an ovarian carcinoma cell line (10). In sum-
mary, it is possible that TC21 controls normal cellular pro-
cesses which are distinct from those that are controlled by Ras
proteins and that aberrant TC21 function causes neoplasms
which are distinct from those associated with mutated Ras.
ACKNOWLEDGMENTS
We thank Carol Martin, Que Lambert, and Sarah Johnson for valu-
able technical assistance and Ashley Overbeck and Jennifer Parrish for
figure and manuscript preparation. We thank Qiming Chen for pro-
viding recombinant MEK and MAPK proteins and Sharon Campbell
for providing recombinant H-Ras, p120-GAP, and NF1-GRD.
This work was supported by Public Health Service grants to C.J.D.
(CA42978, CA55008, and CA63071), A.D.C. (CA61951), and J.A.C.
(54786).
REFERENCES
1. Basu, T. N., D. H. Gutmann, J. A. Fletcher, T. W. Glover, F. S. Collins, and
J. Downward. 1992. Aberrant regulation of ras proteins in malignant tumour
cells from type 1 neurofibromatosis patients. Nature (London) 356:713–715.
2. Beranger, F., B. Goud, A. Tavitian, and J. de Gunzburg. 1991. Association of
the Ras-antagonistic Rap1/Krev-1 proteins with the Golgi complex. Proc.
Natl. Acad. Sci. USA 88:1606–1610.
3. Boguski, M. S., and F. McCormick. 1993. Proteins regulating Ras and its
relatives. Nature (London) 366:643–654.
4. Bollag, G., and F. McCormick. 1992. GTPase activating proteins. Cancer
Biol. 3:199–208.
5. Bollag, G., and F. McCormick. 1995. Intrinsic and GTPase-activating pro-
tein-stimulated Ras GTPase assays. Methods Enzymol. 255:161–170.
6. Bourne, H. R., D. A. Sanders, and F. McCormick. 1990. The GTPase super-
family: conserved structure and molecular mechanism. Nature (London)
349:117–126.
7. Brtva, T. R., J. K. Drugan, S. Ghosh, R. S. Terrell, S. Campbell-Burk, R. M.
Bell, and C. J. Der. 1995. Two distinct Raf domains mediate interaction with
Ras. J. Biol. Chem. 270:9809–9812.
8. Carboni, J. M., N. Yan, A. D. Cox, X. Bustelo, S. M. Graham, M. J. Lynch,
R. Weinmann, B. R. Seizinger, C. J. Der, M. Barbacid, and V. Manne. 1995.
Farnesyltransferase inhibitors are inhibitors of Ras, but not R-Ras/TC21,
transformation. Oncogene 10:1905–1913.
9. Cepko, C. L., B. Roberts, and R. C. Mulligan. 1984. Construction and
applications of a highly transmissible murine retrovirus shuttle vector. Cell
37:1053–1062.
10. Chan, A. M. L., T. Miki, K. A. Meyers, and S. A. Aaronson. 1994. A human
oncogene of the ras superfamily unmasked by expression cDNA cloning.
Proc. Natl. Acad. Sci. USA 91:7558–7562.
11. Chang, E. C., M. Barr, Y. Wang, V. Jung, H.-P. Xu, and M. H. Wigler. 1994.
Cooperative interaction of S. pombe proteins required for mating and mor-
phogenesis. Cell 79:131–141.
12. Chen, S.-Y., S. Y. Huff, C.-C. Lai, C. J. Der, and S. Powers. 1994. Dominant-
negative Ras-15A protein, but not Ras-17N, binds irreversibly to CDC25
GDP-GTP exchange protein. Oncogene 9:2691–2698.
13. Clark, G. J., A. D. Cox, S. M. Graham, and C. J. Der. 1995. Biological assays
for Ras transformation. Methods Enzymol. 255:395–412.
14. Clark, G. J., M. S. Kinch, T. M. Gilmer, K. Burridge, and C. J. Der. 1996.
Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to
the development of human breast cancers. Oncogene 12:169–176.
15. Cook, S. J., B. Rubinfeld, I. Albert, and F. McCormick. 1993. RapV12
antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF
in Rat-1 fibroblasts. EMBO J. 12:3475–3485.
16. Cowley, S., H. Paterson, P. Kemp, and C. J. Marshall. 1994. Activation of
MAP kinase kinase is necessary and sufficient for PC12 differentiation and
for transformation of NIH 3T3 cells. Cell 77:841–852.
17. Cox, A. D., T. R. Brtva, D. G. Lowe, and C. J. Der. 1994. R-Ras induces
malignant, but not morphologic, transformation of NIH3T3 cells. Oncogene
9:3281–3288.
18. Davis, R. J. 1993. The mitogen-activated protein kinase signal transduction
pathway. J. Biol. Chem. 268:14553–14556.
19. DeClue, J. E., A. G. Papageorge, J. A. Fletcher, S. R. Diehl, N. Ratner, W. C.
Vass, and D. R. Lowy. 1992. Abnormal regulation of mammalian p21ras
contributes to malignant tumor growth in von Recklinghausen (type 1)
neurofibromatosis. Cell 69:265–273.
20. Drugan, J. K., R. Khosravi-Far, M. A. White, C. J. Der, Y.-J. Sung, Y.-W.
Huang, and S. L. Campbell. 1996. Ras interaction with two distinct binding
domains in Raf-1 may be required for Ras transformation. J. Biol. Chem.
271:233–237.
21. Egan, S. E., and R. A. Weinberg. 1993. The pathway to signal achievement.
Nature (London) 365:781–783.
22. Feig, L. A. 1993. The many roads that lead to Ras. Science 260:767–768.
23. Feig, L. A., and G. M. Cooper. 1988. Inhibition of NIH 3T3 cell proliferation
by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol.
8:3235–3243.
24. Fields, S., and O. Song. 1989. A novel genetic system to detect protein-
protein interactions. Nature (London) 340:245–246.
25. Frech, M., J. John, V. Pizon, P. Chardi, A. Tavitian, R. Clark, F. McCormick,
and A. Wittinghofer. 1990. Inhibition of GTPase activating protein stimula-
tion of Ras-p21 GTPase by the Krev-1 gene product. Science 249:169–171.
26. Furth, M. E., T. H. Aldrich, and C. Cordon-Cardo. 1987. Expression of ras
proto-oncogene proteins in normal human tissues. Oncogene 1:47–58.
27. Graham, S. M., A. D. Cox, G. Drivas, M. R. Rush, P. D’Eustachio, and C. J.
Der. R-RasB/TC21. InM. Zerial and J. Tooze (ed.), Guidebook to the small
GTPases, in press. Oxford University Press, Oxford.
28. Graham, S. M., A. D. Cox, G. Drivas, M. R. Rush, P. D’Eustachio, and C. J.
Der. 1994. Aberrant function of the Ras-related TC21/R-Ras2 protein trig-
gers malignant transformation. Mol. Cell. Biol. 14:4108–4115.
29. Han, L., and J. Colicelli. 1995. A human protein selected for interference
with Ras function interacts directly with Ras and competes with Raf1. Mol.
Cell. Biol. 15:1318–1323.
30. Harihatan, I. K., R. W. Carthew, and G. M. Rubin. 1991. The Drosophila
roughened mutation: activation of a rap homolog disrupts eye development
and interferes with cell determination. Cell 67:717–722.
31. Hata, Y., A. Kikuchi, T. Sasaki, M. D. Schaber, J. B. Gibbs, and Y. Takai.1990.
Inhibition of the ras p21 GTPase-activating protein-stimulated GTPase ac-
tivity of c-Ha-ras p21 by smg p21 having the same putative effector domain
as ras p21s. J. Biol. Chem. 265:7104–7107.
32. Hauser, C. A., J. K. Westwick, and L. A. Quilliam. 1995. Ras-mediated
transcription activation: analysis by transient cotransfection assays. Methods
Enzymol. 255:412–426.
33. Hofer, F., S. Fields, C. Schneider, and G. S. Martin. 1994. Activated Ras
interacts with the Ral guanine nucleotide dissociation stimulator. Proc. Natl.
Acad. Sci. USA 91:11089–11093.
34. Huff, S. Y., L. A. Quilliam, A. D. Cox, and C. J. Der. R-Ras is regulated by
activators and effectors which are distinct from those that control Ras func-
tion. Oncogene, in press.
35. Joneson, T., M. A. White, M. H. Wigler, and D. Bar-Sagi. 1996. Stimulation
of membrane ruffling and MAP kinase activation by distinct effectors of
RAS. Science 271:810–812.
36. Jung, V., W. Wei, R. Ballester, J. Camonis, S. Mi, L. Van Aelst, M. Wigler,
and D. Broek. 1994. Two types of Ras mutants that dominantly interfere with
activators of Ras. Mol. Cell. Biol. 14:3707–3718.
37. Khosravi-Far, R., and C. J. Der. 1994. The Ras signal transduction pathway.
Cancer Metastasis Rev. 13:67–89.
38. Khosravi-Far, R., P. A. Solski, G. J. Clark, M. S. Kinch, and C. J. Der. 1995.
Activation of Rac, RhoA, and mitogen-activated protein kinases is required
for Ras transformation. Mol. Cell. Biol. 15:6443–6453.
39. Khosravi-Far, R., M. A. White, J. K. Westwick, P. A. Solski, M. Chrza-
nowska-Wodnicka, L. Van Aelst, M. H. Wigler, and C. J. Der. 1996. Onco-
genic Ras activation of Raf/MAP kinase-independent pathways is sufficient
to cause tumorigenic transformation. Mol. Cell. Biol. 16:3923–3933.
40. Kikuchi, A., S. D. Demo, Z.-H. Ye, Y.-W. Chen, and L. T. Williams. 1994.
ralGDS family members interact with the effector loop of ras p21. Mol. Cell.
Biol. 14:7483–7491.
41. Kitayama, H., T. Matsuzaki, Y. Ikawa, and M. Noda. 1990. Genetic analysis
of the Kirsten-ras-revertant 1 gene: potentiation of its tumor suppressor
activity by specific point mutations. Proc. Natl. Acad. Sci. USA 87:4284–
4288.
42. Kitayama, H., Y. Sugimoto, T. Matsuzaki, Y. Ikawa, and M. Noda. 1989. A
ras-related gene with transformation suppressor activity. Cell 56:77–84.
43. Kolch, W., G. Heidecker, P. Lloyd, and U. R. Rapp. 1991. Raf-1 protein
kinase is required for growth of induced NIH/3T3 cells. Nature (London)
349:426–428.
44. Krengel, U., L. Schlichting, A. Scherer, R. Schumann, M. Frech, J. John, W.
Kabsch, E. F. Pai, and A. Wittinghofer. 1990. Three-dimensional structures
of H-ras p21 mutants: molecular basis for their inability to function as signal
switch molecules. Cell 62:539–548.
45. Leevers, S. J., and C. J. Marshall. 1992. MAP kinase regulation—the onco-
gene connection. Trends Cell Biol. 2:283–286.
46. Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K.
Fukasawa, G. F. Vande Woude, and N. G. Ahn. 1994. Transformation of
mammalian cells by constitutively active MAP kinase kinase. Science 265:
966–970.
47. Marais, R., J. Wynne, and R. Treisman. 1993. The SRF accessory protein
Elk-1 contains a growth factor-regulated transcriptional activation domain.
Cell 73:381–393.
48. Marshall, M. S. 1993. The effector interactions of p21ras. Trends Biochem.
Sci. 18:250–254.
49. Milburn, M. V., L. Tong, A. M. DeVos, A. Brunger, Z. Yamaizumi, S.
Nishimura, and S.-H. Kim. 1990. Molecular switch for signal transduction:
VOL. 16, 1996 TC21 SIGNALING 6139
structural differences between active and inactive forms of protooncogenic
ras proteins. Science 247:939–945.
50. Moodie, S. A., and A. Wolfman. 1994. The 3Rs of life: Ras, Raf and growth
regulation. Trends Genet. 10:14–18.
51. Mosteller, R. D., J. Han, and D. Broek. 1994. Identification of residues of the
H-Ras protein critical for functional interaction with guanine nucleotide
exchange factors. Mol. Cell. Biol. 14:1104–1112.
52. Oldham, S. M., G. J. Clark, L. M. Gangarosa, R. J. Coffey, Jr., and C. J. Der.
1996. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras
transformation of RIE-1 epithelial cells. Proc. Natl. Acad. Sci. USA 93:6924–
6928.
53. Polakis, P., and F. McCormick. 1993. Structural requirements for the inter-
action of p21ras with GAP, exchange factors, and its biological effector target.
J. Biol. Chem. 268:9157–9160.
54. Prendergast, G. C., and J. B. Gibbs. 1993. Pathways of Ras function: con-
nections to the actin cytoskeleton. Adv. Cancer Res. 62:19–63.
55. Prendergast, G. C., R. Khosravi-Far, P. A. Solski, H. Kurzawa, P. F. Leb-
owitz, and C. J. Der. 1995. Critical role of RhoB in cell transformation by
oncogenic Ras. Oncogene 10:2289–2296.
56. Qiu, R.-G., J. Chen, F. McCormick, and M. Symons. 1995. A role for Rho in
Ras transformation. Proc. Natl. Acad. Sci. USA 92:11781–11785.
57. Qiu, R.-G., F. McCormick, and M. Symons. 1995. An essential role for Rac
in Ras transformation. Nature (London) 374:457–459.
58. Quilliam, L. A., M. M. Hisaka, S. Zhong, A. Lowry, R. D. Mosteller, J. Han,
J. K. Drugan, D. Broek, S. Campbell, and C. J. Der. 1996. Involvement of the
switch 2 domain of Ras in its interaction with guanine nucleotide exchange
factors. J. Biol. Chem. 271:11076–11082.
59. Quilliam, L. A., S. Y. Huff, K. M. Rabun, W. Wei, D. Broek, and C. J. Der.
1994. Membrane-targetting potentiates CDC25 and SOS activation of Ras
transformation. Proc. Natl. Acad. Sci. USA 91:8512–8516.
60. Quilliam, L. A., K. Kato, K. M. Rabun, M. M. Hisaka, S. Y. Huff, S.
Campbell-Burk, and C. J. Der. 1994. Identification of residues critical for
Ras(17N) growth inhibitory phenotype and for Ras interaction with guanine
nucleotide exchange factors. Mol. Cell. Biol. 14:1113–1121.
61. Quilliam, L. A., R. Khosravi-Far, S. Y. Huff, and C. J. Der. 1995. Activators
of Ras superfamily proteins. Bioessays 17:395–404.
62. Reuter, C. W. M., A. D. Catling, and M. J. Weber. 1995. Immune complex
kinase assays for mitogen-activated protein kinase and MEK. Methods En-
zymol. 255:245–256.
63. Rodriguez-Viciana, P., P. H. Warne, R. Dhand, B. Vanhaesebroeck, I. Gout,
M. J. Fry, M. D. Waterfield, and J. Downward. 1994. Phosphatidylinositol-
3-OH kinase as a direct target of Ras. Nature (London) 370:527–532.
64. Russell, M., C. A. Lange-Carter, and G. L. Johnson. 1995. Direct interaction
between Ras and the kinase domain of mitogen-activated protein kinase
kinase kinase (MEKK1). J. Biol. Chem. 270:11757–11760.
65. Sato, K. Y., P. G. Polakis, H. Haubruck, C. L. Fasching, F. McCormick, and
E. J. Stanbridge. 1994. Analysis of the tumor suppressor activity of the
K-rev-1 gene in human tumor cell lines. Cancer Res. 54:552–559.
66. Schlessinger, J. 1993. How receptor tyrosine kinases activate Ras. Trends
Biochem. Sci. 18:273–275.
67. Schweighoffer, F., H. Cai, M. C. Chevallier-Multon, I. Fath, G. Cooper, and
B. Tocque. 1993. The Saccharomyces cerevisiae SDC25 C-domain gene prod-
uct overcomes the dominant inhibitory activity of Ha-Ras Asn-17. Mol. Cell.
Biol. 13:39–43.
68. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypep-
tides expressed in Escherichia coli as fusions with glutathione S-transferase.
Gene 67:31–40.
69. Spaargaren, M., and J. R. Bischoff. 1994. Identification of the guanine
nucleotide dissociation stimulator for Ral as a putative effector molecule of
R-ras, H-ras, K-ras and Rap. Proc. Natl. Acad. Sci. USA 91:12609–12613.
70. Umanoff, H., W. Edelmann, A. Pellicer, and R. Kucherlapati. 1995. The
murine N-ras gene is not essential for growth and development. Proc. Natl.
Acad. Sci. USA 92:1709–1713.
71. Van Aelst, L., M. Barr, S. Marcus, A. Polverino, and M. Wigler. 1993.
Complex formation between RAS and RAF and other protein kinases. Proc.
Natl. Acad. Sci. USA 90:6213–6217.
72. Van Aelst, L., M. A. White, and M. H. Wigler. 1994. Ras partners. Cold
Spring Harbor Symp. Quant. Biol. 59:181–186.
73. Vojtek, A. B., S. M. Hollenberg, and J. A. Cooper. 1993. Mammalian Ras
interacts directly with the serine/threonine kinase Raf. Cell 74:205–214.
74. White, M. A., C. Nicolette, A. Minden, A. Polverino, L. Van Aelst, M. Karin,
and M. H. Wigler. 1995. Multiple Ras functions can contribute to mamma-
lian cell transformation. Cell 80:533–541.
75. Wu, J., J. K. Harrison, P. Dent, K. R. Lynch, M. J. Weber, and T. W. Sturgill.
1993. Identification and characterization of a new mammalian mitogen-
activated protein kinase kinase, MKK2. Mol. Cell. Biol. 13:4539–4548.
76. Zhang, X., J. Settleman, J. M. Kyriakis, E. Takeuchi-Suzuki, S. J. Elledge,
M. S. Marshall, J. T. Bruder, U. R. Rapp, and J. Avruch. 1993. Normal and
oncogenic p21ras proteins bind to the amino-terminal regulatory domain of
c-Raf-1. Nature (London) 364:308–313.
6140 GRAHAM ET AL. MOL. CELL. BIOL.
